Engineered immune cells battle Tough-to-Treat blood cancer
NCT ID NCT03029338
Summary
This early-phase trial tested a new treatment called CAR-T cell therapy for patients whose B-cell lymphoma had returned or stopped responding to standard treatments. Doctors collected and genetically modified the patients' own immune cells to better target and fight the cancer cells, then infused them back over three days. The main goals were to see if this approach was safe and if it could help control the cancer in these difficult cases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.